<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
<meta http-equiv="Content-Type" content=
"text/html; charset=utf-8" /><!-- AppResources meta begin -->

<script type="text/javascript">
//<![CDATA[
var ncbi_startTime = new Date();
//]]>
</script><!-- AppResources meta end -->
<!-- TemplateResources meta begin -->
<meta name="paf_template" content="" />
<!-- TemplateResources meta end -->
<!-- Logger begin -->
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_pdid" content="article" />
<meta name="ncbi_acc" content="" />
<meta name="ncbi_domain" content="brjclinpharm" />
<meta name="ncbi_report" content="record" />
<meta name="ncbi_type" content="fulltext" />
<meta name="ncbi_objectid" content="" />
<meta name="ncbi_pcid" content="/articles/PMC2015059/" />
<meta name="ncbi_app" content="pmc" /><!-- Logger end -->
<title>Single- and multiple-dose pharmacokinetics of ziprasidone
under non-fasting conditions in healthy male volunteers</title>
<!-- AppResources external_resources begin -->
<link rel="stylesheet" href="/core/jig/1.14.4/css/jig.min.css" />
<script type="text/javascript" src=
"/core/jig/1.14.4/js/jig.min.js">
</script><!-- AppResources external_resources end -->
<!-- Page meta begin -->
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" />
<link rel="canonical" href="/pmc/articles/PMC2015059/" />
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
<meta name="citation_journal_title" content=
"British Journal of Clinical Pharmacology" />
<meta name="citation_title" content=
"Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers" />
<meta name="citation_authors" content=
"J J Miceli, K D Wilner, R A Hansen, A C Johnson, G Apseloff, N Gerber" />
<meta name="citation_date" content="January 2000" />
<meta name="citation_issue" content="Suppl 1" />
<meta name="citation_volume" content="49" />
<meta name="citation_firstpage" content="5S" />
<meta name="citation_doi" content=
"10.1046/j.1365-2125.2000.00147.x" />
<meta name="citation_abstract_html_url" content=
"/pmc/articles/PMC2015059/?report=abstract" />
<meta name="citation_pmid" content="10771448" />
<meta name="DC.Title" content=
"Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers" />
<meta name="DC.Type" content="Text" />
<meta name="DC.Publisher" content="Wiley-Blackwell" />
<meta name="DC.Contributor" content="J J Miceli" />
<meta name="DC.Contributor" content="K D Wilner" />
<meta name="DC.Contributor" content="R A Hansen" />
<meta name="DC.Contributor" content="A C Johnson" />
<meta name="DC.Contributor" content="G Apseloff" />
<meta name="DC.Contributor" content="N Gerber" />
<meta name="DC.Date" content="2000 Jan" />
<meta name="DC.Identifier" content=
"10.1046/j.1365-2125.2000.00147.x" />
<meta name="DC.Language" content="en" />
<meta property="og:title" content=
"Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers" />
<meta property="og:type" content="article" />
<meta property="og:description" content=
"To evaluate the pharmacokinetics and tolerability of single and multiple oral doses of ziprasidone in healthy male volunteers, and to determine the influence of ziprasidone on serum prolactin levels.Single and multiple doses of ziprasidone were given ..." />
<meta property="og:url" content=
"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2015059/" />
<meta property="og:site_name" content="PubMed Central (PMC)" />
<meta property="og:image" content=
"http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:site" content="@ncbi" />
<link rel="stylesheet" href="/corehtml/pmc/css/3.4/pmc.min.css"
type="text/css" />
<link rel="stylesheet" href=
"/corehtml/pmc/css/3.4/pmc_extras_prnt.min.css" type="text/css"
media="print" />
<script type="text/javascript" src=
"/corehtml/pmc/js/common.min.js">
//<![CDATA[
//
//]]>
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/NcbiTagServer.min.js">
//<![CDATA[
//
//]]>
</script>
<meta name="citationexporter" content=
"backend:'/pmc/utils/ctxp/'" />
<script type="text/javascript" src=
"/corehtml/pmc/ctxp/jquery.citationexporter.js">
//<![CDATA[
//
//]]>
</script>
<link rel="stylesheet" href=
"/corehtml/pmc/ctxp/citationexporter.css" type="text/css" />
<script type="text/javascript" src=
"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js">
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/large-obj-scrollbars.min.js">
</script>
<script type="text/javascript">
//<![CDATA[
window.name="mainwindow";
//]]>
</script>
<style type="text/css">
/*<![CDATA[*/
.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
.print-view{display:block}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
/*]]>*/
</style>
<link rel="alternate" type="application/epub+zip" href=
"/pmc/articles/PMC2015059/epub/" />
<link rel="alternate" type="application/pdf" href=
"/pmc/articles/PMC2015059/pdf/bcp0049-005S.pdf" />
<!-- Page meta end -->
<link rel="shortcut icon" href=
"//www.ncbi.nlm.nih.gov/favicon.ico" />
<meta name="ncbi_phid" content=
"F4FB73476FE7D331000000000047D919" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3852956/3985586/3808861/3734262/3974050/3917732/251717/4048120/3846471/14534/45193/3988413/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3411343/3882866/3929378.css"
media="print" />
</head>
<body class="article">
<div class="grid">
<div class="col twelve_col nomargin shadow">
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
<div class="sysmessages"><noscript>
<p class="nojs"><strong>Warning:</strong> The NCBI web site
requires JavaScript to function. <a href=
"/guide/browsers/#enablejs" title="Learn how to enable JavaScript"
target="_blank">more...</a></p>
</noscript></div>
<!--/.sysmessage-->
<div class="wrap">
<div class="page">
<div class="top">
<div class="universal_header" id="universal_header">
<ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id=
"navcontent">
<li class=
"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt">
<a class="ui-ncbimenu-link-first" href="/" role="banner" title=
"NCBI Home" id="ncbihome" accesskey="1"><span class=
"offscreen_noflow">NCBI</span><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/28977"
class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#maincontent" title="Skip to the content" tabindex="0" accesskey=
"3">Skip to main content</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#navcontent" title="Skip to the navigation" tabindex="0"
accesskey="4">Skip to navigation</a></li>
<li id="resource-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset">
<a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href=
"/static/header_footer_ajax/submenu/#resources">Resources</a></li>
<li id="all-howtos-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first"><a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href="/static/header_footer_ajax/submenu/#howto">How To</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"/guide/browsers/#accesskeys" title="About My NCBI Accesskeys"
tabindex="0" accesskey="0">About NCBI Accesskeys</a></li>
</ul>
<div class="myncbi"><span id="myncbiusername" style=
"display:none"><a href="/account/settings/" id="mnu" title=
"Edit account settings"></a></span><a accesskey="2" href="/myncbi/"
id="myncbi" style="display:none">My NCBI</a><a href="/account/" id=
"sign_in">Sign in to NCBI</a><a href="/account/signout/" id=
"sign_out" style="display:none">Sign Out</a></div>
</div>
<div class="header">
<div class="res_logo">
<h1 class="img_logo"><a href="/pmc/" class=
"pmc_logo offscreen">PMC</a></h1>
<div class="NLMLogo"><a href="http://www.nlm.nih.gov/" title=
"US National Library of Medicine">US National Library of
Medicine</a><br />
<a href="http://www.nih.gov/" title=
"National Institutes of Health">National Institutes of
Health</a></div>
</div>
<div class="search">
<form method="get" action="/pmc/">
<div class="search_form"><label for="database" class=
"offscreen_noflow">Search database</label><select id="database">
<optgroup label="Recent">
<option value="pmc" selected="selected" class="last" data-ac_dict=
"pmc-search-autocomplete">PMC</option>
</optgroup>
<optgroup label="All">
<option value="gquery">All Databases</option>
<option value="assembly">Assembly</option>
<option value="bioproject">BioProject</option>
<option value="biosample">BioSample</option>
<option value="biosystems">BioSystems</option>
<option value="books">Books</option>
<option value="clinvar">ClinVar</option>
<option value="clone">Clone</option>
<option value="cdd">Conserved Domains</option>
<option value="gap">dbGaP</option>
<option value="dbvar">dbVar</option>
<option value="epigenomics">Epigenomics</option>
<option value="nucest">EST</option>
<option value="gene">Gene</option>
<option value="genome">Genome</option>
<option value="gds">GEO DataSets</option>
<option value="geoprofiles">GEO Profiles</option>
<option value="nucgss">GSS</option>
<option value="gtr">GTR</option>
<option value="homologene">HomoloGene</option>
<option value="medgen">MedGen</option>
<option value="mesh">MeSH</option>
<option value="ncbisearch">NCBI Web Site</option>
<option value="nlmcatalog">NLM Catalog</option>
<option value="nuccore">Nucleotide</option>
<option value="omim">OMIM</option>
<option value="pmc" data-ac_dict="pmc-search-autocomplete">
PMC</option>
<option value="popset">PopSet</option>
<option value="probe">Probe</option>
<option value="protein">Protein</option>
<option value="proteinclusters">Protein Clusters</option>
<option value="pcassay">PubChem BioAssay</option>
<option value="pccompound">PubChem Compound</option>
<option value="pcsubstance">PubChem Substance</option>
<option value="pubmed">PubMed</option>
<option value="pubmedhealth">PubMed Health</option>
<option value="snp">SNP</option>
<option value="sra">SRA</option>
<option value="structure">Structure</option>
<option value="taxonomy">Taxonomy</option>
<option value="toolkit">ToolKit</option>
<option value="toolkitall">ToolKitAll</option>
<option value="toolkitbook">ToolKitBook</option>
<option value="toolkitbookgh">ToolKitBookgh</option>
<option value="unigene">UniGene</option>
</optgroup>
</select>
<div class="nowrap"><label for="term" class="offscreen_noflow"
accesskey="/">Search term</label>
<div class="nowrap"><input type="text" name="term" id="term" title=
"Search PMC. Use up and down arrows to choose an item from the autocomplete."
value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config=
"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'"
autocomplete="off" data-sbconfig=
"ds:'no',pjs:'no',afs:'yes'" /></div>
<button id="search" type="submit" class="button_search nowrap" cmd=
"go">Search</button></div>
</div>
</form>
<ul class="searchlinks inline_list">
<li><a href="/pmc/limits/">Limits</a></li>
<li><a href="/pmc/advanced/">Advanced</a></li>
<li><a href="/pmc/journals/">Journal list</a></li>
<li class="help"><a target="_blank" href=
"/books/NBK3825/">Help</a></li>
</ul>
</div>
</div>
<!--<component id="Page" label="headcontent"/>--></div>
<div class="content"><!-- site messages -->
<div class="container">
<div id="maincontent" class="content eight_col col">
<div class="navlink-box">
<ul class="page-breadcrumbs inline_list small">
<li class="journal-list"><a href="/pmc/journals/" class=
"navlink">Journal List</a></li>
<li class="archive-page"><a class="navlink" href=
"/pmc/journals/279/">Br J Clin Pharmacol</a></li>
<li class="issue-page"><a class="navlink" href=
"/pmc/issues/151586/">v.49(Suppl 1); 2000 Jan</a></li>
<li class="accid">PMC2015059</li>
</ul>
</div>
<!-- Journal banner -->
<div class="pmc-page-banner whole_rhythm">
<div><img src="/corehtml/pmc/pmcgifs/logo-brjclinpharm.gif" alt=
"Logo of brjclinpharm" usemap="#logo-imagemap" /><map id=
"logo-imagemap" name="logo-imagemap">
<area alt="Link to Publisher's site" title=
"Link to Publisher's site" shape="default" coords="0,0,499,74"
href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251"
target="pmc_ext" ref=
"reftype=publisher&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" />
</map></div>
</div>
<!--component id='MainPortlet' label='search-reference'/-->
<!-- Book content -->
<div class="">
<div class=
"hide-overflow article lit-style content pmc-wm slang-all page-box">
<!--main-content-->
<div class="jig-ncbiinpagenav" data-jigconfig=
"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'">
<div class="fm-sec half_rhythm no_top_margin">
<div class="fm-citation half_rhythm no_top_margin clearfix">
<div class="small">
<div class="inline_block eight_col va_top">
<div>
<div><span class="cit">Br J Clin Pharmacol. 2000 Jan; 49(Suppl 1):
5S–13S.</span></div>
<div><span class="doi">doi:&nbsp; <a href=
"http://dx.doi.org/10.1046%2Fj.1365-2125.2000.00147.x" target=
"pmc_ext" ref=
"reftype=other&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">
10.1046/j.1365-2125.2000.00147.x</a></span></div>
</div>
</div>
<div class=
"inline_block four_col va_top show-overflow align_right">
<div class="fm-citation-ids">
<div class="fm-citation-pmcid"><span class=
"fm-citation-ids-label">PMCID:</span> <span>PMC2015059</span></div>
</div>
</div>
</div>
</div>
<h1 class="content-title">Single- and multiple-dose
pharmacokinetics of ziprasidone under non-fasting conditions in
healthy male volunteers</h1>
<div class="half_rhythm">
<div class="contrib-group fm-author"><a href=
"/pubmed/?term=Miceli%20JJ%5Bauth%5D">J J Miceli</a>,<sup>1</sup>
<a href="/pubmed/?term=Wilner%20KD%5Bauth%5D">K D
Wilner</a>,<sup>1</sup> <a href=
"/pubmed/?term=Hansen%20RA%5Bauth%5D">R A Hansen</a>,<sup>1</sup>
<a href="/pubmed/?term=Johnson%20AC%5Bauth%5D">A C
Johnson</a>,<sup>1</sup> <a href=
"/pubmed/?term=Apseloff%20G%5Bauth%5D">G Apseloff</a>,<sup>2</sup>
and <a href="/pubmed/?term=Gerber%20N%5Bauth%5D">N
Gerber</a><sup>2</sup></div>
</div>
<div class="fm-panel small half_rhythm">
<div class="fm-authors-info fm-panel hide half_rhythm" id=
"id865116_ai" style="display:none">
<div class="fm-affl" lang="en"><sup>1</sup>Department of Clinical
Research, Pfizer Central Research, Groton, CT 06340, USA</div>
<div class="fm-affl" lang="en"><sup>2</sup>Department of
Pharmacology, Ohio State University, Columbus, OH, USA</div>
<div id="cor1"><em>Correspondence:</em> Dr J. J. Miceli, Department
of Clinical Research, Pfizer Central Research, Groton, CT 06340,
USA.</div>
</div>
<div class="togglers"><a href="#" class="pmctoggle" rid=
"id865116_ai">Author information <span>►</span></a> <a href="#"
class="pmctoggle" rid="id865116_cpl">Copyright and License
information <span>►</span></a></div>
<div class="fm-article-notes fm-panel half_rhythm"></div>
<div class="fm-cpl-info fm-panel hide half_rhythm" id=
"id865116_cpl" style="display:none">
<div class="fm-copyright half_rhythm"><a href=
"/pmc/about/copyright.html">Copyright</a> © 2000 Blackwell Science
Ltd</div>
</div>
</div>
<div class="links-box fm-panel whole_rhythm">
<div class="small">
<div>This article has been <a href=
"/pmc/articles/PMC2015059/citedby/">cited by</a> other articles in
PMC.</div>
</div>
</div>
</div>
<div class="sec"></div>
<div id="__abstractid285946" lang="en" class="tsec sec">
<h2 class="head no_bottom_margin" id="__abstractid285946title">
Abstract</h2>
<!--article-meta-->
<div>
<div id="__sec1" class="sec sec-first">
<h3>Aims</h3>
<p id="__p1" class="p p-first-last">To evaluate the
pharmacokinetics and tolerability of single and multiple oral doses
of ziprasidone in healthy male volunteers, and to determine the
influence of ziprasidone on serum prolactin levels.</p>
</div>
<div id="__sec2" class="sec">
<h3>Methods</h3>
<p id="__p2" class="p p-first-last">Single and multiple doses of
ziprasidone were given orally (as two divided daily doses), at
fixed dosages of 10 and 40 mg day<sup>−1</sup>, and using titrated
regimens of 40–80 and 40–120 mg day<sup>−1</sup>, for 14 days. All
dosages were taken immediately after food. The study adopted a
randomized, double-blind, placebo-controlled design. Prolactin
response, sedative properties, tolerability, and extrapyramidal
symptoms were also investigated.</p>
</div>
<div id="__sec3" class="sec">
<h3>Results</h3>
<p id="__p3" class="p p-first-last">Steady-state exposure to
ziprasidone was attained after 1 day of dosing. Mean
<em>C</em><sub>max</sub> and AUC(0,12 h) increased with increasing
dose, with apparent dose-proportionality between the 20 and 60 mg
dose levels. Trough-to-peak ratios at steady state ranged from 2 to
5. Accumulation ratios for the fixed-dose regimens were 1.49 and
1.48 at the 5 and 20 mg dose levels, respectively. Ziprasidone was
associated with transient prolactin elevation but levels of
prolactin returned to baseline within the dosing interval at steady
state. There was a marginal, transient increase in serum prolactin
levels which was not dose-related at the 80 and 120 mg
day<sup>−1</sup> doses, and which was noted to attenuate with
chronic dosing. Ziprasidone was generally well tolerated. The most
frequent side-effect was mild or moderate headache. A minority of
patients suffered first-dose postural hypotension. Ziprasidone was
also associated with a mild sedative effect that became less
pronounced as treatment continued. There were no drug-related
changes in electrocardiogram or clinical laboratory variables that
were of clinical importance.</p>
</div>
<div id="__sec4" class="sec sec-last">
<h3>Conclusions</h3>
<p id="__p4" class="p p-first-last">Ziprasidone is characterized by
a predictable pharmacokinetic profile resulting in symptoms that
reflect its pharmacological action.</p>
</div>
</div>
<div class="sec"><strong class="kwd-title">Keywords:</strong>
<span class="kwd-text">extrapyramidal symptoms, pharmacokinetics,
serum prolactin, ziprasidone</span></div>
</div>
<div id="__sec5" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec5title">
Introduction</h2>
<p id="__p5" class="p p-first">The unique combination of
pharmacological activities of ziprasidone predicts a broad range of
beneficial effects, as well as a low liability for inducing
movement disorders. Laboratory and clinical findings have led to
the hypothesis that preferential antagonism of central
5-HT<sub>2A</sub> receptors by ziprasidone limits its potential to
induce movement disorders, and improves its efficacy against
positive and negative symptoms of schizophrenia [<a href="#b1" rid=
"b1" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012974">1</a>]. This profile appears to offer a potential
advantage over other medications such as risperidone because
clinical experience with this drug suggests that clinical efficacy
in the absence of extrapyramidal symptoms is limited to a narrow
dose range for most patients (4–6 mg day<sup>−1</sup>) [<a href=
"#b2" rid="b2" class=" bibr popnode">2</a>].</p>
<p id="__p6" class="p p-last">The present study was undertaken to
evaluate the pharmacokinetics and tolerability of single and
multiple oral dosages of ziprasidone in healthy male volunteers.
The effect of ziprasidone on serum prolactin levels was also
investigated.</p>
</div>
<div id="__sec6" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec6title">Methods</h2>
<div id="__sec7" class="sec sec-first">
<h3>Subjects</h3>
<p id="__p7" class="p p-first">The study involved 39 healthy male
volunteers aged 18–45 years, whose body weights were between 61 and
91 kg, and who were within 10% of the ideal weight for age and
height [<a href="#b3" rid="b3" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012970">3</a>]. All were nonsmokers. Each had WBC,
neutrophil count, MCH, BUN, and creatinine levels within 10% of the
normal range, and haemoglobin and haematocrit within 5% of the
normal range. The subjects were also required to have urinalysis,
glucose-6-phosphate dehydrogenase, MCV, SGOT, SGPT, and alkaline
phosphatase values within normal limits, and bilirubin &lt; 10%
above the upper limit of normal. Blood pressure was required to be
between 95/65 and 140/90 mmHg, and heart rate between 50 and 100
beats min<sup>−1</sup>.</p>
<p id="__p8">Subjects with any condition thought likely to affect
the absorption of ziprasidone were excluded, as were those with
clinical evidence or history of allergic, haematological, renal,
endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic,
psychiatric or neurological disease, including all forms of
epilepsy. Subjects with known drug or alcohol dependence or drug
allergies were also excluded.</p>
<p id="__p9">None of the subjects had taken prescription,
over-the-counter or recreational drugs for at least 2 weeks before
entering the study and none had received an investigational drug
for at least 4 weeks.</p>
<p id="__p10" class="p p-last">The study protocol was approved by
an independent institutional review board and all subjects provided
informed written consent.</p>
</div>
<div id="__sec8" class="sec">
<h3>Study design</h3>
<p id="__p11" class="p p-first">In this double-blind,
parallel-group study, subjects were randomised to receive placebo
or one of four doses of ziprasidone: 10 mg day<sup>−1</sup>, 40 mg
day<sup>−1</sup>, 40 mg day<sup>−1</sup> escalated to 80 mg
day<sup>−1</sup>, and 40 mg day<sup>−1</sup> escalated to 120 mg
day<sup>−1</sup>. All dosages were given as two divided daily
doses.</p>
<p id="__p12">Earlier trials had indicated that dosage escalation
of ziprasidone might minimize the risk of syncope and/or postural
hypotension. Dosage escalation was therefore used in this study,
but was discontinued if any of the following reactions to the
initial dose occurred: adverse side-effects or reactions; clinical
laboratory abnormalities; decrease in RBC, WBC, neutrophils or
haemoglobin attributable to ziprasidone; significant
electrocardiogram (ECG) abnormalities such as symptomatic
dysrhythmias requiring therapy; 2nd or 3rd degree A–V block, or a
temperature greater than 38°C.</p>
<p id="__p13">In all groups, the first dose was administered on the
morning of day 1, and was followed by a 48 h postdose washout to
obtain blood samples for determination of single-dose
pharmacokinetic data. The 80 and 120 mg day<sup>−1</sup> groups
received a single 20 mg dose on day 1. From days 4–17 medication
was given twice daily (every 12 h) and the final dose was given on
the morning of day 18. For the subjects undergoing dose escalation,
the dose of ziprasidone was increased to 80 mg day<sup>−1</sup> on
day 7 and, in one group, to 120 mg day<sup>−1</sup> on day 10.
After the final dose of ziprasidone on the morning of day 18, all
subjects received single-blind placebo until the final assessments
on day 20.</p>
<p id="__p14">Doses were administered with 50 ml water immediately
after a standard breakfast or a standard evening meal (eaten over
20 min).</p>
<p id="__p15" class="p p-last">Subjects were asked to refrain from
lying down (except for vital sign measurements), and from eating or
drinking caffeinated beverages during the first 4 h postdose on the
mornings of days 1 and 18. Subjects stayed at the clinical research
facility under continuous medical supervision for at least 36 h
before the first dose, and until 72 h after the last dose on day
18.</p>
</div>
<div id="__sec9" class="sec">
<h3>Pharmacokinetic assessments</h3>
<p id="__p16" class="p p-first">Blood samples (8 ml, sufficient to
provide 3 ml of serum) for pharmacokinetic analysis were collected
on days 1 and 18 immediately before dosing and 0.5, 1, 2, 3, 4, 6,
8, 12, 18, 24, 36, 48, and 72 h after dosing. Additional samples
were collected immediately before dosing on days 5–17 to determine
trough serum drug levels. All samples were collected in evacuated
tubes that were free of preservative and anticoagulant and were
stored at room temperature until clotting had occurred. Within 1 h
after collection, the serum was separated from whole blood in a
refrigerated centrifuge and stored at −20°C until analysis.</p>
<p id="__p17">Serum concentrations of ziprasidone were determined
by high performance liquid chromatography (h.p.l.c.) using
liquid–liquid extraction and an atmospheric pressure ionization
mass spectrometry (API-MS) detection method [<a href="#b4" rid="b4"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012963">4</a>]. The lower limit of quantification for the
assay was 0.5 ng ml<sup>−1</sup> and the upper limit was 50 ng
ml<sup>−1</sup>. The assay was linear and accurate within 5% over
this range. Serum concentrations below the lower limit were
assigned a value of 0 ng ml<sup>−1</sup> for the estimation of
pharmacokinetic parameters.</p>
<p id="__p18">The maximum observed serum concentration
(<em>C</em><sub>max</sub>) and the time at which it occurred
(<em>t</em><sub>max</sub>) were estimated directly from individual
plasma concentration–time curves. The terminal phase rate constant,
λ<sub>z</sub>, was estimated using least-squares regression
analysis of the curve during the terminal log-linear phase. The
mean terminal phase half-life, <em>t</em><sub>½,z</sub>, was
calculated as ln 2/mean λ<sub>z.</sub></p>
<p id="__p19">The area under the concentration–time curve from time
zero to time <em>t</em> of the last sample with quantifiable
concentrations of ziprasidone (AUC(0, <em>t</em>)) was estimated
using linear trapezoidal approximation. The area under the
concentration–time curve from time <em>t</em> to infinity
(AUC(<em>t</em>,∞)) was estimated as <em>Cp</em><sub>est</sub>
/λ<sub>z</sub>, where <em>Cp</em><sub>est</sub> was the estimated
concentration at time <em>t</em> based upon the regression
analysis. Area under the serum concentration–time curve from time 0
to infinity (AUC(0, ∞)) was estimated as the sum of AUC(0,
<em>t</em>) and AUC(<em>t</em>,∞). Area under the curve from time
0–12 h postdose, AUC(0,12 h), was also estimated using linear
trapezoidal approximation.</p>
<p id="__p20" class="p p-last">For the two groups in which there
was no dose escalation, the accumulation ratio (R) was determined
from the ratio of the day 18 AUC(0,12 h)/day 1 AUC(0,12 h).
Similarly, the predicted accumulation ratio after the first dose
(R′) was estimated from the ratio of the day 1 AUC(0,∞)/day 1
AUC(0,12 h).</p>
</div>
<div id="__sec10" class="sec">
<h3>Serum prolactin</h3>
<p id="__p21" class="p p-first-last">Blood samples for the
determination of serum prolactin concentrations were collected 0.25
and 0.5 h before the first dose of ziprasidone or placebo on day 1.
Additional samples were collected at the same times as the
pharmacokinetic samples. Serum was separated from whole blood as
described above. Serum prolactin was assayed using standard
methods.</p>
</div>
<div id="__sec11" class="sec">
<h3>Tolerability</h3>
<p id="__p22" class="p p-first">Sedation was evaluated by subject
self-report. In total, 12 categories related to sedation (drowsy,
sleepy, slowed down, sedated, tired, worn out, listless, fatigued,
exhausted, sluggish, weary, bushed) were scored using a scale of 0
(absent) to 7 (severe). Sedation profiles were undertaken: within
24 h before dosing on day 1 at 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48
h after the first dose; prior to morning and evening dosage on days
4–17; prior to and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and
120 h postdose on day 18. The subjects also completed a
standardized sleep profile self-rating scale immediately after
waking on days 1–23. Eleven questions related to sleep were
evaluated by means of an analogue scale (e.g. with extremes of ‘not
at all’ to ‘definitely’). The subjects also indicated how long they
had taken to fall asleep, the duration of uninterrupted sleep and
the incidence of waking during the night.</p>
<p id="__p23">Extrapyramidal symptoms were evaluated using the
Simpson–Angus rating scale [<a href="#b5" rid="b5" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012966">5</a>]. Each subject was scored on a scale of 0
(absent) to 4 (extreme) for each of the following 10 categories:
gait, arm dropping, shoulder shaking, elbow rigidity, fixation of
position or wrist rigidity, leg pendulousness, head dropping,
glabella tap, tremor, and salivation.</p>
<p id="__p24">Subjects were observed and questioned regarding the
presence of akathisia according to the method of Barnes [<a href=
"#b6" rid="b6" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012975">6</a>]. For this assessment, the signs and
symptoms of various categories of akathisia observed by the
investigator were scored on a scale of 0 (none) to 3 (severe) with
the subject in the sitting, standing, and lying positions.</p>
<p id="__p25">A global evaluation based on the Abnormal Involuntary
Movement Scale (AIMS) was also undertaken in which abnormal
movements, incapacitation due to abnormal movements, and the
subject’s awareness of abnormal movements were scored by the
investigator on a scale of 0 (none) to 4 (severe) [<a href="#b7"
rid="b7" class=" bibr popnode">7</a>].</p>
<p id="__p26">These three assessments were undertaken at the
following times: within 24 h of the first dose of trial medication;
2, 12, and 24 h postdose on day 1; prior to administration of the
morning dose on days 4, 6, 8, 10, 12, 14, and 16; and 0, 2, 12, 24,
48, 72, 96, and 120 h postdose on day 18.</p>
<p id="__p27">All observed or volunteered adverse events occurring
up to 6 days after the last dose were recorded together with
details of onset, duration, severity (mild, moderate, severe),
treatment required, and an assessment of the possible relationship
to study treatment. The events were classified by body system using
the preferred terms of the COSTART system.</p>
<p id="__p28">Routine clinical laboratory tests (haematology and
clinical chemistry) were undertaken at the screening visit,
immediately prior to administration of ziprasidone or placebo on
days 1, 4, 10 and 18; 24 h postdose on day 1 and 72 h postdose on
day 18. Additional liver function tests were performed on day 0
(within 24 h prior to the first dose of ziprasidone or placebo);
and at 24 and 48 h after dosing on day 18. Dipstick urinalysis was
undertaken with microscopic evaluation of the sediment.</p>
<p id="__p29" class="p p-last">Standing and supine blood pressures
and pulse rates were measured at approximately the same time as the
clinical laboratory assessments. A standard 12-lead ECG was
obtained for each subject at screening; at 0, 1, 4, 10, 18 and 24 h
postdose on day 1; and 72 h after the morning dose on day 18. Oral
temperature was recorded at the same time.</p>
</div>
<div id="__sec12" class="sec sec-last">
<h3>Statistical analysis</h3>
<p id="__p30" class="p p-first-last">There were no formal
statistical analyses. <em>C</em><sub>max</sub>, AUC(0,12 h) and
AUC(0,∞) were measured by geometric means and standard deviations.
Arithmetic means and standard deviations were calculated for all
other parameters except <em>t</em><sub>½,z</sub>. Changes in serum
prolactin at each time point on days 1 and 18 were described using
means and standard deviations. Extrapyramidal side-effects
including akathisia and Parkinsonian symptoms, AIMS scores,
sedation and sleep ratings were summarized descriptively.</p>
</div>
</div>
<div id="__sec13" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec13title">Results</h2>
<div id="__sec14" class="sec sec-first">
<h3>Subjects</h3>
<p id="__p31" class="p p-first">A total of 39 subjects entered the
study. Baseline characteristics were similar in each of the five
treatment groups (<a href="/pmc/articles/PMC2015059/table/tbl1/"
target="true" class="fig-table-link table figpopup" rid-figpopup=
"tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table
1</span></a>).</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl1"><a href="/pmc/articles/PMC2015059/table/tbl1/" target=
"table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class=
"table img_link icnblk_img figpopup"><img alt="Table 1" title=
"Table 1" class="small-thumb" src=
"/pmc/articles/PMC2015059/table/tbl1/?report=thumb" src-large=
"/pmc/articles/PMC2015059/table/tbl1/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015059/table/tbl1/" target="table" rid-figpopup=
"tbl1" rid-ob="ob-tbl1">Table 1</a></div>
<!--caption a4-->
<div><span>Baseline demographic data</span></div>
</div>
</div>
<p id="__p33" class="p p-last">Two subjects in the 40 mg
day<sup>−1</sup> group and one subject in the 40–80 mg
day<sup>−1</sup> group discontinued the study as a result of
treatment-related postural hypotension. In the 40 mg
day<sup>−1</sup> group, postural hypotension followed the initial
dose of ziprasidone on day 1. In the 40–80 mg day<sup>−1</sup>
group, postural hypotension was observed on day 9. An additional
six subjects, four from the placebo group and one each from the
40–80 mg day<sup>−1</sup> and 40–120 mg day<sup>−1</sup> groups,
discontinued for reasons not related to treatment. All those who
discontinued ziprasidone were excluded from the pharmacokinetic
evaluation at day 18 but were included in the evaluation on day
1.</p>
</div>
<div id="__sec15" class="sec">
<h3>Single-dose pharmacokinetics</h3>
<p id="__p34" class="p p-first">Mean <em>C</em><sub>max</sub>
following a single 5 mg dose of ziprasidone was 12.2 ng
ml<sup>−1</sup> compared with values between 26.6 and 60.0 ng
ml<sup>−1</sup> in the three groups receiving ziprasidone at an
initial dose of 20 mg (<a href=
"/pmc/articles/PMC2015059/table/tbl2/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob=
"ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). Mean
<em>t</em><sub>max</sub> values in the 10 and 40 mg
day<sup>−1</sup> dose groups were similar, with values ranging from
approximately 4–5 h. The serum concentration–time profiles for the
four treatment groups are shown in <a href=
"/pmc/articles/PMC2015059/figure/fig01/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure
1</span></a>.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl2"><a href="/pmc/articles/PMC2015059/table/tbl2/" target=
"table" rid-ob="ob-tbl2" rid-figpopup="tbl2" class=
"table img_link icnblk_img figpopup"><img alt="Table 2" title=
"Table 2" class="small-thumb" src=
"/pmc/articles/PMC2015059/table/tbl2/?report=thumb" src-large=
"/pmc/articles/PMC2015059/table/tbl2/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015059/table/tbl2/" target="table" rid-figpopup=
"tbl2" rid-ob="ob-tbl2">Table 2</a></div>
<!--caption a4-->
<div><span>Summary of pharmacokinetic parameters (mean±s.d.)
following single (5 and 20 mg day<sup>−1</sup>) and multiple (10,
40, 80 and 120 mg day<sup>−1</sup>) doses of ziprasidone in healthy
male subjects in the fed state.</span></div>
</div>
</div>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01"
co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2015059/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01"><img src=
"/pmc/articles/PMC2015059/bin/bcp0049-005S-f1.gif" class=
"small-thumb" alt="Figure 1" title="Figure 1" src-large=
"/pmc/articles/PMC2015059/bin/bcp0049-005S-f1.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig01">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015059/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div>
<!--caption a4-->
<div><span>Serum concentration–time profiles following
administration of single (a) and multiple (b) oral doses of
ziprasidone to healthy male volunteers immediately after food.
Dosages of ziprasidone were 10 mg day<sup>−1</sup> (•), 40 mg
day<sup>−1</sup></span> <strong>...</strong></div>
</div>
</div>
<p id="__p38" class="p p-last">Mean λ<sub>z</sub> values were
similar across all four groups, ranging from 0.143 to 0.220
h<sup>−1</sup> and corresponded to mean half-lives between 3.2 and
4.8 h. Mean AUC(0,12 h) was 73.7 ng ml<sup>−1</sup> h after the 5
mg dose and between 175.7 and 314.6 ng ml<sup>−1</sup>h in the
groups that received a 20 mg dose. The predicted geometric mean
accumulation ratios were 1.18 for the single 5 mg dose and 1.29 at
the single 20 mg dose.</p>
</div>
<div id="__sec16" class="sec">
<h3>Multiple-dose pharmacokinetics</h3>
<p id="__p39" class="p p-first">Trough serum concentrations between
days 5 and 17 suggested that steady-state conditions were attained
within 1 day of dosing. Mean <em>C</em><sub>max</sub> was higher in
all dose groups on day 18 than on day 1 (<a href=
"/pmc/articles/PMC2015059/table/tbl2/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob=
"ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). Day 18
<em>C</em><sub>max</sub> values were dose-related, ranging from
14.8 ng ml<sup>−1</sup> in the 10 mg day<sup>−1</sup> group to
139.4 ng ml<sup>−1</sup> in the 120 mg day<sup>−1</sup> group
(<a href="/pmc/articles/PMC2015059/table/tbl2/" target="true"
class="fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob=
"ob-tbl2" co-legend-rid=""><span>Table 2</span></a>; <a href=
"/pmc/articles/PMC2015059/figure/fig01/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>).
The rate of absorption was similar in all groups and appeared
unchanged following multiple dosing as indicated by similar values
for <em>t</em><sub>max</sub> on days 1 and 18 (<a href=
"/pmc/articles/PMC2015059/table/tbl2/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob=
"ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). In addition,
steady-state normalized <em>C</em><sub>max</sub> values were
similar in all four groups.</p>
<p id="__p40">Drug exposure estimated by AUC(0,12 h) increased with
dose from a mean of 109.8 ng ml <sup>−1</sup>h in the 10 mg
day<sup>−1</sup> group to 1027.9 ng ml <sup>−1</sup>h in the 120 mg
day<sup>−1</sup> group. With the exception of the 10 mg
day<sup>−1</sup> regimen, steady-state AUC(0,12 h) normalized for
dose increased with increasing dose. At the end of the dosing
period the observed geometric mean accumulation ratios for the 10
mg day<sup>−1</sup> and 40 mg day<sup>−1</sup> groups were 1.49 and
1.48, respectively (<a href="/pmc/articles/PMC2015059/table/tbl2/"
target="true" class="fig-table-link table figpopup" rid-figpopup=
"tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table
2</span></a>).</p>
<p id="__p41" class="p p-last">As shown in <a href=
"/pmc/articles/PMC2015059/table/tbl2/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob=
"ob-tbl2" co-legend-rid=""><span>Table 2</span></a>, the mean
terminal phase elimination rate constant was smaller in the 80 mg
day<sup>−1</sup> and 120 mg day<sup>−1</sup> groups on day 18 than
in the 10 mg day<sup>−1</sup> or 40 mg day<sup>−1</sup> groups.
This was related to the appearance of an additional disposition
phase. The harmonic mean terminal phase half-lives ranged from 4 to
5 h in the 10 mg day<sup>−1</sup> and 40 mg day<sup>−1</sup> groups
to 8–10 h in the 80 mg day<sup>−1</sup> and and 120 mg
day<sup>−1</sup> groups. The peak-to-trough concentration ratios
generally ranged from 2 to 5 across all dose groups.</p>
</div>
<div id="__sec17" class="sec">
<h3>Serum prolactin concentrations</h3>
<p id="__p42" class="p p-first">With both single and chronic
dosing, ziprasidone was associated with a transient, marginal
elevation in serum prolactin which returned to baseline within the
dosing interval at all ziprasidone doses (<a href=
"/pmc/articles/PMC2015059/table/tbl3/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl3" rid-ob=
"ob-tbl3" co-legend-rid=""><span>Table 3</span></a>). Maximum
prolactin elevations associated with ziprasidone occurred 2–6 h
postdose, corresponding with <em>t</em><sub>max</sub> for
ziprasidone plasma concentrations.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl3"><a href="/pmc/articles/PMC2015059/table/tbl3/" target=
"table" rid-ob="ob-tbl3" rid-figpopup="tbl3" class=
"table img_link icnblk_img figpopup"><img alt="Table 3" title=
"Table 3" class="small-thumb" src=
"/pmc/articles/PMC2015059/table/tbl3/?report=thumb" src-large=
"/pmc/articles/PMC2015059/table/tbl3/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015059/table/tbl3/" target="table" rid-figpopup=
"tbl3" rid-ob="ob-tbl3">Table 3</a></div>
<!--caption a4-->
<div><span>Serum prolactin concentrations (ng ml<sup>−1</sup>)
(change from baseline).</span></div>
</div>
</div>
<p id="__p45">There was no evidence of a dose-relationship at 80 or
120 mg day<sup>−1</sup> as shown by the magnitude of the maximum
postdose elevation, which was actually lower for 120 mg
day<sup>−1</sup> than 80 mg day<sup>−1</sup> on day 18. Plasma
concentration–time curves for these two doses on day 18 confirm
that while serum ziprasidone concentrations were dose-related,
serum prolactin concentrations were not.</p>
<p id="__p46" class="p p-last">In addition, there appeared to be
some attenuation of the transient prolactin elevation with multiple
ziprasidone dosing compared with single dosing. With multiple
ziprasidone dosing there was pharmacokinetic accumulation, as shown
by the increase in AUC(0,12 h) normalized for dose, between days 1
and 18 in the 10 mg day<sup>−1</sup> and 40 mg day<sup>−1</sup>
groups. However, this accumulation was not matched by proportionate
increases in serum prolactin levels between days 1 and 18 at these
doses.</p>
</div>
<div id="__sec18" class="sec">
<h3>Sedation and sleep profiles</h3>
<p id="__p47" class="p p-first">Ziprasidone was associated with
mild sedation compared with placebo following the administration of
single 5 and 20 mg doses on day 1. The peak mean scores (i.e. the
mean summated score from 7-point assessments in 12 different
categories, where a maximum score of 84 would imply extreme
sedation) were 17.7, 15.4, 22.6 and 21.3 in the 10, 40, 40–80 and
40–120 mg day<sup>−1</sup> groups, respectively. Sedation occurred
earlier with the single 20 mg dose (3 h) than with the single 5 mg
dose (8 h). Mean sedation scores on day 18 were similar to day 1
baseline scores and placebo in the 10, 40, 40–80 and 40–120 mg
day<sup>−1</sup> groups (<a href=
"/pmc/articles/PMC2015059/figure/fig02/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob=
"ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>).
The 40–120 mg day<sup>−1</sup> group experienced mild sedation
(peak mean score 25.8) between 2 and 8 h postdose.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig02"
co-legend-rid="lgnd_fig02"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2015059/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02"><img src=
"/pmc/articles/PMC2015059/bin/bcp0049-005S-f2.gif" class=
"small-thumb" alt="Figure 2" title="Figure 2" src-large=
"/pmc/articles/PMC2015059/bin/bcp0049-005S-f2.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig02">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015059/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02">Figure 2</a></div>
<!--caption a4-->
<div><span>Mean change from baseline in sum of sedation scores on
day 18 profiles following administration of multiple oral doses of
ziprasidone 10 mg day<sup>−1</sup> (•), 40 mg day<sup>−1</sup> (□),
40–80 mg day<sup>−1</sup> (▴) and 40–120</span>
<strong>...</strong></div>
</div>
</div>
<p id="__p49" class="p p-last">The sleep profile remained
relatively stable for all dose groups throughout the treatment
period. However, at the end of double-blind treatment with
ziprasidone at dosages ≥ 40 mg day<sup>−1</sup>, the mean time to
fall asleep increased by between 70 and 84 min and the mean
duration of sleep decreased from baseline values of 6.11–6.36 h by
between 2.25 h and 3.93 h.</p>
</div>
<div id="__sec19" class="sec sec-last">
<h3>Adverse events</h3>
<p id="__p50" class="p p-first">Thirty-one of the 39 subjects who
entered the study reported a total of 112 adverse events (<a href=
"/pmc/articles/PMC2015059/table/tbl4/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob=
"ob-tbl4" co-legend-rid=""><span>Table 4</span></a>). Similar
numbers of subjects in each of the five treatment groups
experienced adverse events although the total number of adverse
events was higher in the ziprasidone 40, 40–80 and 40–120 mg
day<sup>−1</sup> groups compared with placebo. The most frequently
occurring adverse event was headache. This was generally mild or
moderate in severity, except for two subjects in the 40 mg
day<sup>−1</sup> group. One subject had severe headache on days 11
and 16, which began 10.9 and 9.8 h after ziprasidone administration
and lasted 4.3 and 12.5 h, respectively. The other subject had
severe headache on day 3 that began 55.3 h after initial dosing and
lasted 7.2 h.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl4"><a href="/pmc/articles/PMC2015059/table/tbl4/" target=
"table" rid-ob="ob-tbl4" rid-figpopup="tbl4" class=
"table img_link icnblk_img figpopup"><img alt="Table 4" title=
"Table 4" class="small-thumb" src=
"/pmc/articles/PMC2015059/table/tbl4/?report=thumb" src-large=
"/pmc/articles/PMC2015059/table/tbl4/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015059/table/tbl4/" target="table" rid-figpopup=
"tbl4" rid-ob="ob-tbl4">Table 4</a></div>
<!--caption a4-->
<div><span>Summary of treatment-emergent adverse
events</span></div>
</div>
</div>
<p id="__p52">Nine subjects had Simpson–Angus scores of 1 (three in
the 40 mg day<sup>−1</sup> group, five in the 40–80 mg
day<sup>−1</sup> group and one in the 40–120 mg day<sup>−1</sup>
group) indicating the presence of mild extrapyramidal symptoms.
Only one of the nine subjects reported tremor as an adverse event
(on day 12, duration 48 h). One other subject reported tremor (day
14, duration 19 h), but his Simpson–Angus score remained at 0 for
the duration of the study. No subject had an AIMS score or Barnes
akathisia score above 0 at any time.</p>
<p id="__p53">Seven subjects developed postural hypotension, and in
three subjects the episodes were severe (two at 40–120 mg
day<sup>−1</sup> and one at 40 mg day<sup>−1</sup>). Two subjects
with postural hypotension, both in the 40 mg day<sup>−1</sup>
group, were withdrawn from the study after the first dose of
ziprasidone, one with moderate and one with severe symptoms. A
third subject (40–80 mg day<sup>−1</sup> group) was withdrawn after
9 days of treatment because of moderate postural hypotension whilst
receiving ziprasidone at 80 mg day<sup>−1</sup>. Six subjects
experienced dizziness which was severe in two subjects, and four
subjects experienced somnolence. All severe episodes of dizziness,
hypotension, or somnolence occurred on the first day of dosing, in
four of the 23 subjects who received ziprasidone at 40 mg
day<sup>−1</sup>.</p>
<p id="__p54">A reduction in mean supine diastolic blood pressure
was observed in the 40 mg day<sup>−1</sup> group, and between days
10 and 18 this was more marked than in the other groups. The
changes in diastolic blood pressure at higher dosages were not
different from those after placebo. However, mean reductions from
baseline in standing systolic blood pressure between 4 and 8 h
postdose on day 1 were more marked in all ziprasidone groups than
with placebo. This effect diminished during multiple dosing.</p>
<p id="__p55" class="p p-last">There were no clinically significant
ECG findings related to treatment with ziprasidone, nor were there
clinically important trends or abnormalities in any of the
laboratory test variables.</p>
</div>
</div>
<div id="__sec20" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec20title">Discussion</h2>
<p id="__p56" class="p p-first">The objective of the present study
was to evaluate the pharmacokinetics and tolerability of a range of
single and multiple oral doses of ziprasidone in order to help
define a suitable dosage regimen for Phase III clinical trials. The
effect of ziprasidone administration on serum prolactin levels was
also evaluated. The rationale for administering ziprasidone after
food was based on our previous unpublished studies (Pfizer Inc.,
data on file) that showed that the presence of food in the stomach
increases oral bioavailability. Steady-state conditions were
generally attained after 1 day of dosing over the 10–120 mg
day<sup>−1</sup> dose range.</p>
<p id="__p57">The overall exposure to ziprasidone at steady-state
appeared dose-proportional between 40 and 120 mg day<sup>−1</sup>
based on dose-adjusted mean AUC(0,12 h) values. The adjusted
AUC(0,12 h) values for the 10 mg day<sup>−1</sup> dose level
appeared to be disproportionately large. The relationship between
<em>C</em><sub>max</sub> and dose was similar to that observed for
AUC(0,12 h).</p>
<p id="__p58">Multiple-dose administration resulted in increased
pharmacokinetic variability compared with single doses. This was
inferred from increases in coefficients of variation for
<em>C</em><sub>max</sub> and AUC(0,12 h) between days 1 and 18.
However, the degree of pharmacokinetic variability was not
dose-dependent. Individual steady-state values ranged approximately
three- to seven-fold but intersubject variability was as high as
20-fold in the 40 mg day<sup>−1</sup> group.</p>
<p id="__p59">At steady-state, the terminal half-life at the 80 and
120 mg day<sup>−1</sup> dosage levels was longer (9–10 h) than that
observed with the 10–40 mg day<sup>−1</sup> dosages (4–5 h). The
longer half-lives were related to the detection of an additional
disposition phase which only became apparent following multiple
dosing; this finding was not related to a dose-dependent decrease
in oral clearance. The observed accumulation at the 10 and 40 mg
day<sup>−1</sup> dose levels was greater than that predicted by
first-dose parameters of 30% and 24%, respectively. This may, in
part, be related to an underestimation of AUC(0,∞) at low doses due
to an inability to characterize the additional disposition
phase.</p>
<p id="__p60">At clinically effective doses (80 and 120 mg
day<sup>−1</sup>), ziprasidone was not associated with sustained
prolactin elevation in men. Although there was a marginal,
transient elevation in prolactin, this was not dose-related at the
80 and 120 mg day<sup>−1</sup> doses with levels returning to
baseline within the dosing interval. In addition, the slight
increase in maximum serum prolactin concentration was not apparent
12 h after dosing at steady state.</p>
<p id="__p61">The lack of sustained prolactin elevation with
ziprasidone is in contrast to the effect of older neuroleptic
agents such as haloperidol, which is associated with marked and
sustained prolactin elevation as a consequence of very potent
D<sub>2</sub> receptor antagonism [<a href="#b8" rid="b8" class=
" bibr popnode">8</a>]. This also contrasts with the newer
antipsychotic agent, risperidone, which is also associated with
hyperprolactinaemia [<a href="#b9" rid="b9" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012978">9</a>–<a href="#b15" rid="b15" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012971">15</a>]. The slight, transient prolactin
elevation associated with ziprasidone in this study is similar to
that observed with clozapine [<a href="#b16" rid="b16" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012969">16</a>] which, in general, does not induce
clinically significant hyperprolactinaemia [<a href="#b17" rid=
"b17" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012981">17</a>, <a href="#b18" rid="b18" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012979">18</a>].</p>
<p id="__p62">The lack of sustained hyperprolactinaemia with
ziprasidone may reflect its relatively short plasma elimination
half-life of approximately 6–8 h because the pituitary lactotrophs,
which are responsible for prolactin release, are situated outside
the blood–brain barrier and may not therefore be exposed to
ziprasidone for prolonged periods [<a href="#b19" rid="b19" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012972">19</a>, <a href="#b20" rid="b20" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012968">20</a>]. If ziprasidone is cleared less rapidly
from the central nervous system than from the plasma, this may
explain why ziprasidone has sufficient pharmacodynamic activity at
central D<sub>2</sub> receptors to reduce psychotic symptoms but
does not cause hyperprolactinaemia. In addition, the constellation
of serotonergic activities of ziprasidone (i.e. very potent
antagonism at 5-HT<sub>2A</sub> receptors, potent antagonism at
5-HT<sub>2C</sub> and 5-HT<sub>1D</sub> receptors, and agonist
activity at 5-HT<sub>1A</sub> receptors) may also contribute to the
lack of hyperprolactinaemia.</p>
<p id="__p63">The adverse effects of sustained hyperprolactinaemia
include sexual dysfunction, particularly in men [<a href="#b21"
rid="b21" class=" bibr popnode">21</a>, <a href="#b21" rid="b21"
class=" bibr popnode">22</a>], which is a major cause of medication
noncompliance in patients with schizophrenia [<a href="#b22" rid=
"b22" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012977">23</a>]. In addition, hyperprolactinaemia is also
associated with galactorrhoea, gynaecomastia and amenorrhoea
[<a href="#b23" rid="b23" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012976">24</a>], and possibly with decreased bone mineral
density and subsequent increased risk of fracture [<a href="#b24"
rid="b24" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012964">25</a>, <a href="#b25" rid="b25" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012980">26</a>]. The fact that ziprasidone does not
induce hyperprolactinaemia in men is encouraging as this may
translate into improved tolerability and compliance compared with
conventional neuroleptics and some of the newer antipsychotic
agents. Long-term clinical trials will further evaluate this aspect
of ziprasidone’s activity.</p>
<p id="__p64">The most frequently occurring adverse event was mild
or moderate headache. A minority of subjects experienced adverse
events rated as severe, including headache, orthostatic
hypotension, somnolence and dizziness. These were predominantly
first-dose effects and reflect experience from preliminary
pharmacokinetic studies (Pfizer Inc., data on file). Orthostatic
hypotension is thought to reflect α<sub>1</sub>-adrenoceptor
blockade. In this respect ziprasidone has been shown to have lesser
propensity to produce orthostatic hypotension than that of other
antipsychotic agents, including olanzapine, quetiapine and
sertindole [<a href="#b26" rid="b26" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012962">27</a>].</p>
<p id="__p65">None of the subjects displayed a maximum
Simpson-Angus score of &gt; 1 and most maintained a score of zero
throughout the trial despite steady-state administration of
therapeutic doses. In all cases, extrapyramidal symptoms were mild
or absent, and there was no evidence of dose-dependency. Moreover,
no positive AIMS scores or akathisia determinations were noted for
any subject. These findings confirm the predicted low incidence of
movement disorders with ziprasidone on the basis of its potent
antagonism at 5-HT<sub>2</sub> receptors [<a href="#b1" rid="b1"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012965">1</a>].</p>
<p id="__p66">Although single doses of ziprasidone were associated
with an increase in sedation scores which reached a peak at
<em>t</em><sub>max</sub>, a relevant sedative effect was noted only
in the 40–120 mg day<sup>−1</sup> group on the last day of dosing,
providing additional evidence that tolerance develops on repeated
dosing. In support of this hypothesis, it has been proposed that
sedative effects caused by new antipsychotic agents are related to
antagonism of central H<sub>1</sub> receptors, and in comparative
studies ziprasidone has been shown to have less affinity for
H<sub>1</sub> receptors than do risperidone, olanzapine and
remoxipride [<a href="#b25" rid="b25" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012967">26</a>]. In 4- and 6-week clinical trials,
ziprasidone has been shown to be associated with somnolence, which
was generally of mild or moderate severity, and which attenuated
during the studies [<a href="#b27" rid="b27" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012973">28</a>].</p>
<p id="__p67" class="p p-last">In summary, the results of this
study indicate that ziprasidone has a predictable pharmacokinetic
profile characterized by rapid attainment of steady-state and
dose-proportional <em>C</em><sub>max</sub> and AUC(0,12 h).
Systemic ziprasidone exposure following 14 days of multiple dosing
increases with doses ranging between 10 and 120 mg
day<sup>−1</sup>, and is associated with symptoms consistent with
the pharmacological properties of the drug.</p>
</div>
<div id="__ref-listid873593" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ref-listid873593title">
References</h2>
<div class="ref-list-sec sec" id="reference-list">
<div class="ref-cit-blk half_rhythm" id="b1">1. <span class=
"element-citation">Seeger TF, Seymour PA, Schmidt AW, et al.
Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine
and serotonin receptor antagonist activity. <span><span class=
"ref-journal">J Pharmacol Exp Ther.</span> 1995;<span class=
"ref-vol">275</span>:101–113.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7562537" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b2">2. <span class=
"element-citation">Bersani G, Bressa GM, Meco G, et al. Combined
serotonin 5HT<sub>2</sub> and dopamine D<sub>2</sub> antagonism in
schizophrenia: clinical. Extrapyramidal and neuroendocrine response
in a preliminary study with risperidone (R 64766)
<span><span class="ref-journal">Hum Psychopharmacol.</span>
1990;<span class="ref-vol">5</span>:225–231.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b3">3. <span class=
"element-citation">Metropolitan height and weight tables
<span><span class="ref-journal">Stat Bull Metrop Life Found.</span>
1983;<span class="ref-vol">64</span>:3–9.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/6623350" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b4">4. <span class=
"element-citation">Janiszewski JS, Fouda HG, Cole RO. Development
and validation of a high-sensitivity assay for an antipsychotic
agent, CP-88,059, with solid-phase extraction and narrow-bone,
high-performance liquid chromatography. <span><span class=
"ref-journal">J Chromatogr.</span> 1995;<span class=
"ref-vol">668</span>:133–139.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7550970" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b5">5. <span class=
"element-citation">Simpson GM, Angus JW. A rating scale for
extrapyramidal side effects. <span><span class="ref-journal">Acta
Psychiatr Scand.</span> 1970;<span class=
"ref-vol">212</span>(Suppl):11–19.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/4917967" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b6">6. <span class=
"element-citation">Barnes TRE. A rating scale for drug-induced
akathisia. <span><span class="ref-journal">Br J Psychiatr.</span>
1989;<span class="ref-vol">154</span>:672–676.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/2574607" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b7">7. <span class=
"element-citation">Guy W. Abnormal Involuntary Movement Scale. In:
Guy W, editor. <span class="ref-journal">ECDEU Assessment Manual
for Psychopharmacology.</span> Maryland, USA: Department of Health
and Human Services Publication (ADM-76–338); 1976.</span></div>
<div class="ref-cit-blk half_rhythm" id="b8">8. <span class=
"element-citation">Rubin RT. Prolactin and schizophrenia. In:
Meltzer HY, editor. <span class="ref-journal">Psychopharmacology:
the Third Generation of Progress.</span> New York: Raven Press;
1984. pp. 803–808.</span></div>
<div class="ref-cit-blk half_rhythm" id="b9">9. <span class=
"element-citation">Mesotten F, Suy E, Pietquin M, et al.
Therapeutic effect and safety of increasing doses of risperidone (R
64766) in psychotic patients. <span><span class=
"ref-journal">Psychopharmacology.</span> 1989;<span class=
"ref-vol">99</span>:445–459.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/2480616" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b10">10. <span class=
"element-citation">Muller-spahn F. Risperidone in the treatment of
chronic schizophrenic patients: an international double-blind,
parallel-group study versus haloperidol. <span><span class=
"ref-journal">Clin Neuropharmacol.</span> 1992;<span class=
"ref-vol">15</span>(1A):825–835.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/1379882" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b11">11. <span class=
"element-citation">DeCoster R, Bowden C, Byloos M, et al. Endocrine
effects of the new antipsychotic risperidone. Presented at the
<em>9thInternational Congress of Endocrinology</em>, Nice,
France.</span></div>
<div class="ref-cit-blk half_rhythm" id="b12">12. <span class=
"element-citation">Claus A, Bollen J, De Cuyper H, et al.
Risperidone versus haloperidol in the treatment of chronic
schizophrenic inpatients: a multicentre, double-blind, comparative
study. <span><span class="ref-journal">Acta Psychiatr Scand.</span>
1992;<span class="ref-vol">85</span>:295–305.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/1375801" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b13">13. <span class=
"element-citation">Ereshefsky L, Lacombe S. Pharmacological profile
of risperidone. <span><span class="ref-journal">Can J
Psychiatry.</span> 1993;<span class=
"ref-vol">38</span>:S80–S88.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7504573" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b14">14. <span class=
"element-citation">Cardoni AA. Risperidone: review and assessment
of its role in the treatment of schizophrenia. <span><span class=
"ref-journal">Ann Pharmacother.</span> 1995;<span class=
"ref-vol">29</span>:610–618.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7545034" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b15">15. <span class=
"element-citation">Umbricht D, Kane JM. Risperidone: efficacy and
safety. <span><span class="ref-journal">Schizophr Bull.</span>
1995;<span class="ref-vol">21</span>:593–606.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8749887" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b16">16. <span class=
"element-citation">Lee HS, Kim CH, Song SH, Choi NK, Yoo KJ.
Clozapine does not elevate serum prolactin levels in healthy men.
<span><span class="ref-journal">Biol Psychiatry.</span>
1995;<span class="ref-vol">38</span>:762–764.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8580231" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b17">17. <span class=
"element-citation">Meltzer HY. The mechanism of action of novel
antipsychotic drugs. <span><span class="ref-journal">Schizophr
Bull.</span> 1991;<span class="ref-vol">17</span>:263–287.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/1679253" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b18">18. <span class=
"element-citation">Meltzer HY. Treatment of neuroleptic
non-responsive schizophrenic patients. <span><span class=
"ref-journal">Schizophr Bull.</span> 1992;<span class=
"ref-vol">18</span>:515–542.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/1357741" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b19">19. <span class=
"element-citation">Muller EE, Locatelli V, Cella S, Penalva A,
Novelli A, Cocchi D. Prolactin-lowering and releasing drugs.
<span><span class="ref-journal">Drugs.</span> 1983;<span class=
"ref-vol">25</span>:399–432.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/6133737" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b20">20. <span class=
"element-citation">De Koning P, de Vries MH. A comparison of the
neuro-endocrinological and temperature effects of DU 29894,
flesinoxan, sulpiride and haloperidol in normal volunteers.
<span><span class="ref-journal">Br J Clin Pharmacol.</span>
1995;<span class="ref-vol">39</span>:7–14.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC1364975/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/7756102" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b21">21. <span class=
"element-citation">Rojansky N, Wang K, Halbreich U. <span class=
"ref-journal">Adverse Effects of Psychotropic Drugs.</span>
Guildford Press: 1992. Reproductive and sexual adverse effects on
psychotropic drugs; pp. 356–375.</span></div>
<div class="ref-cit-blk half_rhythm" id="b22">22. <span class=
"element-citation">Schwartz MF, Bauman JE, Masters WH.
Hyperprolactinaemia and sexual disorders in men. <span><span class=
"ref-journal">Biol Psychiatry.</span> 1982;<span class=
"ref-vol">17</span>:861–876.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7115837" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b23">23. <span class=
"element-citation">Fleischhacker WW, Meise U, Gunther V, et al.
Compliance with antipsychotic drug treatment: influence of side
effects. <span><span class="ref-journal">Acta Psychiatr
Scand.</span> 1994;<span class="ref-vol">89</span>:11–15.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/7916523" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b24">24. <span class=
"element-citation">Buvat J, Lemaire A, Buvat-herbaut M, et al.
Hyperprolactinemia and sexual function in men. <span><span class=
"ref-journal">Hormone Res.</span> 1985;<span class=
"ref-vol">22</span>:196–203.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/4054839" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b25">25. <span class=
"element-citation">Ataya K, Mercado A, Kartiaginer J, et al. Bone
density and reproductive hormones in patients with
neuroleptic-induced hyperprolactinemia. <span><span class=
"ref-journal">Fertil Steril.</span> 1988;<span class=
"ref-vol">50</span>:876–881.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/2904890" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b26">26. <span class=
"element-citation">Halbreich U, Rojansky N, Palter S, et al.
Decreased bone mineral density in medicated psychiatric patients.
<span><span class="ref-journal">Psychosomatic Med.</span>
1995;<span class="ref-vol">57</span>:485–491.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8552740" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b27">27. <span class=
"element-citation">Pickar D. Prospects for pharmacotherapy of
schizophrenia. <span><span class="ref-journal">Lancet.</span>
1995;<span class="ref-vol">345</span>:557–562.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7539875" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015059&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b28">28. <span class=
"element-citation">Tandon R, Harrigan E, Zorn SH. Ziprasidone: a
novel antipsychotic with unique therapeutic potential.
<span><span class="ref-journal">J Serotonin Res.</span>
1997;<span class="ref-vol">4</span>:159–177.</span></span></div>
</div>
</div>
</div>
<!--post-content-->
<hr class="whole_rhythm no_bottom_margin" />
<div class="courtesy-note no_margin small">Articles from
<span class="acknowledgment-journal-title">British Journal of
Clinical Pharmacology</span> are provided here courtesy of
<strong>British Pharmacological Society</strong></div>
</div>
</div>
<!-- Book content --></div>
<div id="rightcolumn" class="four_col col last">
<!-- Custom content above discovery portlets -->
<div class="col6"></div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance">
<div class="try-button"><a href=
"/pmc/articles/PMC2015059/?report=reader"><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/3838809"
alt="PubReader format: click here to try" /></a></div>
<div class="format-menu">
<h2>Formats:</h2>
<ul>
<li class="selected">Article</li>
<li style="list-style: none">|</li>
<li><a href=
"/pmc/articles/PMC2015059/?report=reader">PubReader</a></li>
<li style="list-style: none">|</li>
<li class="epub-link"><a href="/pmc/articles/PMC2015059/epub/">ePub
(beta)</a></li>
<li style="list-style: none">|</li>
<li><a href="/pmc/articles/PMC2015059/pdf/bcp0049-005S.pdf">PDF
(163K)</a></li>
<li style="list-style: none">|</li>
<li><a href="#" data-citationid="PMC2015059" class=
"citationexporter ctxp">Citation</a></li>
</ul>
</div>
</div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance" class="share-buttons">
<h2>Share</h2>
<ul>
<li class="facebook"><a href=
"https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2015059%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047626"
alt="Share on Facebook" /> Facebook</a></li>
<li class="twitter"><a href=
"https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2015059%2F&amp;text=Single-%20and%20multiple-dose%20pharmacokinetics%20of%20ziprasidone%20under%20non-fasting%20conditions%20in%20healthy%20male%20volunteers">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047627"
alt="Share on Twitter" /> Twitter</a></li>
<li class="gplus"><a href=
"https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2015059%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047628"
alt="Share on Google Plus" /> Google+</a></li>
</ul>
</div>
<div id="ajax-portlets" data-pmid="10771448" data-aiid="2015059"
data-aid="2015059" data-iid="151586" data-domainid="279"
data-domain="brjclinpharm" data-accid="PMC2015059" data-md5=
"7da8d87b0be268fec579a61e2e6ffb8b"></div>
<!-- Custom content below discovery portlets -->
<div class="col7"></div>
</div>
</div>
<!-- Custom content after all -->
<div class="col8"></div>
<div class="col9"></div>
<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js">
</script> <script>
<![CDATA[
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
]]>
</script>
<div id="body-link-poppers"></div>
</div>
<div class="bottom">
<div id="NCBIFooter_dynamic">
<div class="breadcrumbs">You are here: <span id=
"breadcrumb_text"><a href="/guide/">NCBI</a> &gt; <a href=
"http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt;
<a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central
(PMC)</a></span></div>
<a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target=
"_blank" href=
"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-04-01T09:54:16-04:00&amp;Host=ptpmc201">Write
to the Help Desk</a></div>
<div class="footer" id="footer">
<div class="subfooter"></div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/preloaderWidget.js">
</script>
<div id="external-disclaimer" class="offscreen_noflow">External
link. Please review our <a href=
"http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div>
<div id="ncbifooter" class="contact_info">
<div id="footer-contents-right">
<div id="nlm_thumb_logo"><a href="http://www.nlm.nih.gov" title=
"NLM">NLM</a></div>
<div id="nih_thumb_logo"><a href="http://www.nih.gov" title=
"NIH">NIH</a></div>
<div id="hhs_thumb_logo"><a href="http://www.dhhs.gov" title=
"DHHS">DHHS</a></div>
<div id="usagov_thumb_logo"><a href="http://www.usa.gov" title=
"USA.gov">USA.gov</a></div>
</div>
<div id="footer-contents-left"><a href=
"/About/disclaimer.html">Copyright</a> | <a href=
"/About/disclaimer.html#disclaimer">Disclaimer</a> | <a href=
"http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a>
| <a href="/guide/browsers/">Browsers</a> | <a href=
"http://www.nlm.nih.gov/accessibility.html">Accessibility</a> |
<a href="/About/glance/contact_info.html">Contact</a>
<p class="address vcard"><span class="url"><a class=
"fn url newdomain" href="http://www.ncbi.nlm.nih.gov">National
Center for Biotechnology Information</a>,</span> <span class=
"org url"><a href="http://www.nlm.nih.gov/">U.S. National Library
of Medicine</a></span> <span class="adr"><span class=
"street-address">8600 Rockville Pike</span>, <span class=
"locality">Bethesda</span> <span class="region">MD</span>,
<span class="postal-code">20894</span> <span class=
"country-name">USA</span></span></p>
</div>
</div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1">
</script> <script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/hfjs2.js">
</script></div>
</div>
</div>
<!--/.page--></div>
<!--/.wrap--></div>
<!-- /.twelve_col --></div>
<!-- /.grid -->
 <!-- BESelector tab -->
 <noscript><img alt="statistics" src=
"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=brjclinpharm&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2015059/&amp;ncbi_app=pmc" />
</noscript> <!-- usually for JS scripts at page bottom -->
 <!--<component id="PageFixtures" label="styles"></component>-->
 
<!-- F4FB73476FE7D871_0071SID /projects/PMC/PMCViewer@4.35 ptpmc201 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->
 <script type="text/javascript" src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/js/3879255/3728312/3818874/3821238/4064716/4072593/4064449/3921943/4070217/4065628.js"
snapshot="pmc">
</script>
</body>
</html>
